aTyr Pharma Inc LIFE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if LIFE is a good fit for your portfolio.
News
-
aTyr Pharma to Participate in April Investor Conferences
-
aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update
-
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results
-
aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants
-
aTyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity
Trading Information
- Previous Close Price
- $1.60
- Day Range
- $1.54–1.62
- 52-Week Range
- $1.08–2.70
- Bid/Ask
- $1.17 / $1.98
- Market Cap
- $108.37 Mil
- Volume/Avg
- 306,541 / 579,340
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 242.22
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 59
- Website
- https://www.atyrpharma.com
Comparables
Valuation
|
Metric
|
LIFE
|
PLRX
|
KROS
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.11 | 1.50 | 5.19 |
Price/Sales | 242.22 | 441.50 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
LIFE
PLRX
KROS
Financial Strength
|
Metric
|
LIFE
|
PLRX
|
KROS
|
|---|---|---|---|
Quick Ratio | 8.09 | 17.43 | 13.63 |
Current Ratio | 8.33 | 17.72 | 14.25 |
Interest Coverage | — | −145.34 | — |
Quick Ratio
LIFE
PLRX
KROS
Profitability
|
Metric
|
LIFE
|
PLRX
|
KROS
|
|---|---|---|---|
Return on Assets (Normalized) | −39.11% | −22.68% | −35.62% |
Return on Equity (Normalized) | −50.15% | −24.50% | −39.15% |
Return on Invested Capital (Normalized) | −43.68% | −28.46% | −41.95% |
Return on Assets
LIFE
PLRX
KROS
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Vflhvvyqjb | Xbq | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Fwjmnstg | Lsplsz | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Rbclbwpxt | Qqcqrgr | $97.8 Bil | |
MRNA
| Moderna Inc | Zjxktjzyh | Yxqkc | $38.8 Bil | |
ARGX
| argenx SE ADR | Rvnltbgx | Djfs | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Wzzhnty | Ykmy | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Vvbkcdhyj | Gxjbh | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Jklbmwg | Lwsxbjc | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ncscwhgv | Cpwjk | $12.5 Bil | |
INCY
| Incyte Corp | Rhszzlpm | Lmnmvjs | $11.5 Bil |